NeoGenomics Reports Second Quarter 2023 Results

2 years ago

Second Quarter Revenue Increased 18% to $147 MillionFORT MYERS, FL / ACCESSWIRE / August 8, 2023 / NeoGenomics, Inc. (NASDAQ:NEO)…

Zomedica to Present at Sidoti Virtual Investor Conference August 16-17

2 years ago

ANN ARBOR, MI / ACCESSWIRE / August 8, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or "Company"), a veterinary health…

Alpha Pro Tech, Ltd. Announces Second Quarter 2023 Financial Results

2 years ago

Net sales for the second quarter of 2023 were $16.1 million, down 7.2%, compared to $17.4 million for the second…

Published Analysis of Sotagliflozin (INPEFA(TM)) Clinical Data Demonstrates Significant Reductions in the Risk of Hospital Readmissions for Heart Failure

2 years ago

Post-Hoc Analysis of SOLOIST-WHF Clinical Data Published in Journal of the American College of Cardiology: Heart Failure Risk Reductions of…

Precipio Launches Its Much-Anticipated Quantitative BCR-ABL 2.0 Panel

2 years ago

Advanced panel already generating six-figure pre-ordersNEW HAVEN, Conn., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc.…

Chiesi Group Mid-Year Financial Results Demonstrate Strong Growth for 2023

2 years ago

Chiesi Group announces mid-year turnover of €1,497 millionSubstantial growth of each of Chiesi’s business areasEurope remains the biggest market, followed…

NRC Health unveils winners of 2023 patient experience and loyalty awards

2 years ago

LINCOLN, Neb., Aug. 08, 2023 (GLOBE NEWSWIRE) -- NRC Health, a leading provider of Human Understanding® and data-driven insights, is…

Sofwave Medical Reports Second Quarter and First Half 2023 Financial Results and Recent Business Highlights

2 years ago

–  Second quarter revenue of $12.4M, +53% year-over-year growth–  Second quarter pulse recurring revenue of $3.3M, +100% year-over-year growth–  First…

Viracta Therapeutics Announces Publication in Blood Advances Demonstrating Promising and Durable Signal of Nana-val Efficacy in Patients with Relapsed or Refractory (R/R) Epstein-Barr Virus-Positive (EBV+) Lymphoma

2 years ago

Results from Phase 1b/2 trial showed complete responses achieved and ongoing durable responses observed out to approximately 36 months across…

Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent Restenosis

2 years ago

Virtue® Sirolimus AngioInfusion Balloon (“SAB”) is the only non-coated angioplasty system providing protected delivery of extended release sirolimus under clinical…